Späth PJ - Search Results

1

Naturally occurring antibodies/autoantibodies in polyclonal immunoglobulin concentrates.

Späth PJ, Lutz HU. Späth PJ, et al. Adv Exp Med Biol. 2012;750:239-61. doi: 10.1007/978-1-4614-3461-0_18. Adv Exp Med Biol. 2012. PMID: 22903679 Review.

2

Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level.

Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R, Jelezarova E, Späth PJ. Lutz HU, et al. Among authors: spath pj. Blood. 2004 Jan 15;103(2):465-72. doi: 10.1182/blood-2003-05-1530. Epub 2003 Sep 25. Blood. 2004. PMID: 14512320 Free article.

3

Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation.

Lutz HU, Späth PJ. Lutz HU, et al. Among authors: spath pj. Clin Rev Allergy Immunol. 2005 Dec;29(3):207-12. doi: 10.1385/CRIAI:29:3:207. Clin Rev Allergy Immunol. 2005. PMID: 16391395 Review.

4

High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes.

Lutz HU, Stammler P, Jelezarova E, Nater M, Späth PJ. Lutz HU, et al. Among authors: spath pj. Blood. 1996 Jul 1;88(1):184-93. Blood. 1996. PMID: 8704173 Free article.

5

A C3 convertase assay for nephritic factor functional activity.

Jelezarova E, Schlumberger M, Sadallah S, Späth PJ, Schifferli JA, Lutz HU. Jelezarova E, et al. Among authors: spath pj. J Immunol Methods. 2001 May 1;251(1-2):45-52. doi: 10.1016/s0022-1759(01)00295-2. J Immunol Methods. 2001. PMID: 11292480

6

Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations.

Späth PJ, Schneider C, von Gunten S. Späth PJ, et al. Arch Immunol Ther Exp (Warsz). 2017 Jun;65(3):215-231. doi: 10.1007/s00005-016-0422-x. Epub 2016 Sep 16. Arch Immunol Ther Exp (Warsz). 2017. PMID: 27638480 Free article. Review.

7

Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies.

Sudo M, Miyaji K, Späth PJ, Morita-Matsumoto K, Yamaguchi Y, Yuki N. Sudo M, et al. Among authors: spath pj. Int Immunopharmacol. 2016 Nov;40:11-15. doi: 10.1016/j.intimp.2016.08.019. Epub 2016 Aug 24. Int Immunopharmacol. 2016. PMID: 27567246

8

IVIG--mechanisms of action.

Simon HU, Späth PJ. Simon HU, et al. Among authors: spath pj. Allergy. 2003 Jul;58(7):543-52. doi: 10.1034/j.1398-9995.2003.00239.x. Allergy. 2003. PMID: 12823109 Review.

9

Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.

Altznauer F, von Gunten S, Späth P, Simon HU. Altznauer F, et al. J Allergy Clin Immunol. 2003 Dec;112(6):1185-90. doi: 10.1016/j.jaci.2003.09.045. J Allergy Clin Immunol. 2003. PMID: 14657880

10

Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition.

Sudo M, Yamaguchi Y, Späth PJ, Matsumoto-Morita K, Ong BK, Shahrizaila N, Yuki N. Sudo M, et al. Among authors: spath pj. PLoS One. 2014 Sep 26;9(9):e107772. doi: 10.1371/journal.pone.0107772. eCollection 2014. PLoS One. 2014. PMID: 25259950 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

112 results

Search Page

Filters